Inhibition of cortico-amygdala projections underlies affective bias modification by psilocybin

This study demonstrates that psilocybin's rapid and sustained antidepressant effects are mediated by the modulation of affective biases through the 5HT1A/5HT2A receptor-dependent suppression of excitatory inputs to prelimbic cortico-amygdala projection neurons, which subsequently shifts to enhanced inhibitory input and mimics the drug's behavioral effects when these neurons are chemogenetically inhibited.

The Gist

The Big Picture: Resetting the Emotional Compass

Imagine your brain has a compass that points toward how you feel about the world. In people with depression, this compass is stuck pointing "North" toward sadness, fear, and negativity. Even when good things happen, the compass refuses to turn toward happiness.

This study investigates psilocybin (the active compound in "magic mushrooms") not just as a drug that makes you feel good temporarily, but as a mechanic that can fix the compass itself. The researchers wanted to know: How does a single dose of this drug permanently shift a depressed brain from negative to positive?

The Discovery: A Specific Circuit Breaker

The researchers found that psilocybin doesn't just "turn up the volume" on happiness everywhere in the brain. Instead, it acts like a smart dimmer switch on a very specific wire.

1. The Location: The action happens in the Prefrontal Cortex (PrL), which is the brain's "CEO" or the executive office responsible for decision-making and emotional regulation.
2. The Wire: Specifically, it targets the wires connecting the CEO to the Amygdala, the brain's "alarm system" or "fear center."
3. The Action: When the CEO is depressed, it sends too many "danger" signals to the alarm system. Psilocybin works by cutting the power to these specific "danger" wires.

The Two-Step Magic Trick

The study revealed that psilocybin works in two distinct phases, like a two-step renovation project:

Phase 1: The Immediate Silence (The "Mute" Button)

When psilocybin first hits the brain, it acts like a noise-canceling headphone for the fear signals.

• It selectively silences the neurons that send fear signals from the CEO to the alarm system.
• Interestingly, it doesn't silence everything. It actually turns up the volume on other, non-fearful connections. It's like muting the screaming alarm while turning up the music in the living room.
• The Catch: This immediate silence requires two specific keys to work: the 5-HT2A and 5-HT1A receptors. If you block either key, the drug stops working. It's a dual-lock system.

Phase 2: The Long-Term Remodeling (The "Re-wiring")

The most exciting part of the study is what happens 24 hours later.

• Usually, drugs wear off quickly. But here, the silence didn't just return; it deepened.
• The brain didn't just stop sending fear signals; it started receiving more "calm" signals (inhibitory input) to those same fear neurons.
• The Analogy: Imagine the fear neurons were a row of rowdy kids in a classroom.
  • Hour 0: The teacher (psilocybin) tells them to be quiet.
  • Hour 24: The teacher has installed a permanent "Quiet Zone" rule. The kids are now naturally quieter because the environment has changed, not just because the teacher is shouting.
• This "re-wiring" explains why the antidepressant effects last for weeks or months after just one dose.

The Proof: Turning Off the Switch

To prove that silencing this specific wire was the cause of the mood change (and not just a side effect), the researchers used chemogenetics (a high-tech way to control brain cells with a remote control).

• They created a "remote control" that could turn off only the fear-sending neurons in the CEO.
• When they pressed the button to turn these neurons off, the rats immediately stopped feeling negative and started learning new, positive things.
• The Result: This perfectly mimicked the effects of the drug. This proved that silencing the fear wire is the secret sauce behind the therapy.

Why This Matters

This study changes how we think about treating depression.

• Old Idea: Depression is a chemical imbalance that needs to be "filled up" with more serotonin (like adding water to a dry bucket).
• New Idea: Depression is a broken circuit where the fear system is stuck on "high." Psilocybin works by re-routing the traffic, specifically turning down the volume on the fear signals and letting the brain learn new, positive patterns.

Summary in One Sentence

Psilocybin acts like a master electrician who finds the specific, broken wire connecting the brain's "fear center" to its "decision center," cuts the power to the fear, and rewires the system so that 24 hours later, the brain naturally stays calm and open to positive experiences.

Technical Summary

1. Problem Statement

Major Depressive Disorder (MDD) is a leading cause of disability globally, yet current treatments (e.g., SSRIs) often suffer from delayed onset and limited efficacy. Rapid-acting antidepressants (RAADs) like psilocybin show promise for producing rapid and sustained improvements in mood, but the precise neural mechanisms remain unclear.

• Key Gap: While psilocybin is known to modulate "negative affective biases" (a core neuropsychological feature of MDD where negative information is prioritized), the specific cell types, circuits, and receptor mechanisms driving these rapid and enduring behavioral changes are not defined.
• Hypothesis: The study posits that psilocybin acts on specific subregions of the medial prefrontal cortex (mPFC) to alter synaptic transmission in projection-specific neurons, thereby rebalancing emotional processing networks.

2. Methodology

The study employed a multimodal translational approach combining behavioral pharmacology, ex-vivo electrophysiology, and chemogenetics in male Lister Hooded rats.

• Behavioral Models:
  • Affective Bias Test (ABT): Rats were trained to associate digging substrates with food rewards. A negative affective bias was induced using the benzodiazepine inverse agonist FG-7142. Psilocybin's ability to attenuate this bias (acute) and facilitate re-learning of positive associations (sustained, 24h post-treatment) was measured.
  • New Learning Paradigm: Assessed the ability of psilocybin to positively bias the formation of new reward memories.
• Pharmacological Manipulation:
  • Systemic vs. Local: Effects of systemic psilocybin were compared to direct intra-prelimbic (PrL) mPFC infusions of psilocin (active metabolite).
  • Receptor Antagonism: The roles of 5-HT1A (WAY-100635) and 5-HT2A (volinanserin) receptors were tested using selective antagonists administered systemically or locally.
• Electrophysiology (Ex-vivo Slices):
  • Retrograde Labeling: Neurons projecting from the PrL to the Basolateral Amygdala (BLA) were identified using Cholera Toxin subunit b (CTb). This allowed differentiation between Cortico-Amygdala (CA) neurons and non-labeled Cortico-Cortical (CC) or control neurons.
  • Recordings: Whole-cell voltage-clamp recordings measured Excitatory Post-Synaptic Currents (EPSCs), Miniature EPSCs (mEPSCs), and Miniature Inhibitory Post-Synaptic Currents (mIPSCs) to assess synaptic strength, release probability, and plasticity.
• Chemogenetics:
  • A dual-viral strategy (retro-cre in BLA + DIO-hM4D(Gi)-mCherry in PrL) was used to selectively express inhibitory DREADDs (Gi-coupled) in CA projection neurons.
  • Administration of the agonist deschloroclozapine (DCZ) allowed for the specific inhibition of CA neurons to test if this mimics psilocybin's effects.

3. Key Contributions

• Circuit Specificity: Identified the Prelimbic (PrL) subregion of the mPFC as the critical locus for psilocybin's modulation of affective bias.
• Cell-Type Specificity: Demonstrated that psilocin exerts bidirectional, cell-type-specific effects: it suppresses excitatory drive onto CA projection neurons while enhancing drive onto other (putative cortico-cortical) neurons.
• Receptor Mechanism: Established that the modulation of affective biases and the synaptic depression of CA neurons require the coordinated signaling of both 5-HT1A and 5-HT2A receptors, challenging the view that 5-HT2A is the sole mediator.
• Temporal Dynamics: Revealed a shift in synaptic plasticity over time: acute suppression of excitatory input transitions to enhanced inhibitory input (increased mIPSC amplitude and frequency) onto CA neurons 24 hours post-treatment, correlating with sustained behavioral effects.
• Causal Link: Proved that chemogenetic inhibition of CA neurons alone is sufficient to replicate both the acute and sustained behavioral effects of psilocybin.

4. Key Results

A. Behavioral Findings

• PrL Infusion: Direct infusion of psilocin (300 nM or 1 µM) into the PrL attenuated FG-7142-induced negative affective bias, mimicking systemic psilocybin.
• Sustained Effects: PrL infusion produced sustained attenuation of negative bias and facilitation of positive re-learning 24 hours later.
• Receptor Dependence: Systemic pretreatment with either WAY-100635 (5-HT1A antagonist) or volinanserin (5-HT2A antagonist) completely blocked both the acute and sustained behavioral effects of psilocybin.

B. Electrophysiological Findings

• Acute Effects (0h):
  • Psilocin induced a bimodal distribution of responses in PrL Layer 5 pyramidal neurons.
  • CA Neurons: Selectively showed depression of excitatory synaptic input (EPSCs).
  • Non-labeled (CC) Neurons: Selectively showed potentiation of excitatory synaptic input.
  • Mechanism: This depression in CA neurons was blocked by either 5-HT1A or 5-HT2A antagonists, indicating parallel receptor requirements.
• Sustained Effects (24h):
  • No changes were observed in evoked EPSCs or mEPSCs (excitatory drive) 24 hours post-treatment.
  • Crucial Finding: There was a significant increase in mIPSC amplitude and frequency specifically in CA neurons, but not in CC or control neurons. This suggests a homeostatic shift toward enhanced inhibition of the CA circuit to maintain the suppressed state.

C. Chemogenetic Validation

• Selective inhibition of CA neurons via DREADDs (DCZ) successfully:
  1. Acutely attenuated negative affective bias.
  2. Facilitated re-learning of positive valence 24 hours later.
  3. Positively biased new reward memories.
• This confirms that the inhibition of CA output is sufficient to drive the therapeutic behavioral phenotype.

5. Significance and Implications

• Mechanistic Insight: The study moves beyond the "global plasticity" hypothesis, proposing that psilocybin acts by rebalancing specific prefrontal-limbic circuits. It suggests that therapeutic efficacy arises from the selective suppression of maladaptive fear/negative processing pathways (PrL $\to$ BLA) rather than indiscriminate cortical excitation.
• Receptor Nuance: The finding that both 5-HT1A and 5-HT2A receptors are required highlights the importance of poly-pharmacology in psychedelic therapeutics. This challenges the prevailing dogma that 5-HT2A activation alone is sufficient for antidepressant effects.
• Therapeutic Targeting: The identification of CA neurons as a specific substrate offers a potential target for precision therapies. If future drugs can selectively dampen PrL-BLA projections without global psychedelic effects, they might offer RAAD benefits with fewer side effects.
• Translational Validity: By linking a rodent affective bias task (a validated translational model for human cognitive bias) to specific circuit mechanisms, the study provides a robust framework for understanding how rapid-acting antidepressants work in humans, potentially explaining the durability of psilocybin's effects through long-term inhibitory plasticity.

In summary, this paper provides a high-resolution circuit-level explanation for how psilocybin treats depression: by engaging both 5-HT1A and 5-HT2A receptors to acutely suppress and subsequently enhance the inhibition of cortico-amygdala projections in the prelimbic cortex, thereby resetting negative emotional biases.